Latest Anika Therapeutics Inc (ANIK) Headlines
Post# of 30
Uptrend Call Working As Anika Therapeutics Stock Rises 21.7% (ANIK)
Comtex SmarTrend(R) - Mon Mar 10, 9:18AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 2 weeks, Anika Therapeutics has returned 21.70% as of today's recent price of $42.20.
Mutual Funds Loading Up On These 3 Top-Rated Stocks
at Investor's Business Daily - Fri Mar 07, 7:02AM CST
Investors who follow the big money to snag prospective stock winners will find their way to Ubiquiti Networks (UBNT), Diamondback Energy (FANG) and Anika Therapeutics (ANIK) . Today's Screen Of The Day is Accelerating Mutual Fund Ownership....
Global and Chinese Hyaluronic Acid Solution Industry Report 2014
M2 - Wed Mar 05, 2:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/g7vv9d/global_and) has announced the addition of the "Global and Chinese Hyaluronic Acid Solution Industry Report 2014" report to their offering. The Global and Chinese Hyaluronic Acid Solution Industry Report 2014 is a professional and in-depth study on the current state of the global hyaluronic acid solution industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. Hyaluronic acid solution market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Hyaluronic acid solution industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. A key feature of the report is its focus on key industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. Hyaluronic acid solution industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered - Hyaluronic Acid Solution Industry Overview - Hyaluronic Acid Solution International and China Market Analysis - Hyaluronic Acid Solution Development Environmental Analysis - Hyaluronic Acid Solution Development Policy and Plan - Hyaluronic Acid Solution Manufacturing Process and Cost Structure - 2009-2014 Hyaluronic Acid Solution Productions Supply Sales Demand Market Status and Forecast - Hyaluronic Acid Solution Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Hyaluronic Acid Solution Marketing Channels Analysis - 2014-2019 Hyaluronic Acid Solution Productions Supply Sales Demand Market Status and Forecast - Hyaluronic Acid Solution Industry Development Proposals - Hyaluronic Acid Solution New Project Investment Feasibility Analysis - Global and China Hyaluronic Acid Solution Industry Research Conclusions Companies Mentioned - Abbott Medical Optics - Allergan - Anika Therapeutics - Bausch Lomb - Bloomage Freda - CONTIPRO - Changzhou Institute of Material Medical - EME - Ferring Pharmaceuticals - Genzyme Biosurgery - Hangzhou Gallop - Hao Hai Healthcare - Henan Universe IOL - Hyaltech - Jingfeng - LG LIFE & SCIENCE - Lipo Chemicals - Medicis Aesthetics - Merz Pharmaceuticals - Novozymes - Q-Med - Seikagaku - Shiseido - Singclean Medical - Stanford Chemicals - Synvisc-One For more information visit http://www.researchandmarkets.com/research/g7vv9d/global_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Anika Therapeutics to Present at Canaccord Genuity Musculoskeletal Conference March 11
Business Wire - Tue Mar 04, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will be presenting at the 9th Annual Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 12:30 p.m. ET/ 11:30 a.m. CT. The conference is being held at the Sheraton New Orleans Hotel.
Insider Trading Alert - SWK, ANIK And NYT Traded By Insiders
at The Street - Tue Mar 04, 9:15AM CST
Stocks with insider trader activity include SWK, ANIK and NYT
Ukraine Unrest Sparks Selling But Some Biotechs Firm Up
at Investor's Business Daily - Mon Mar 03, 3:22PM CST
Major averages suffered a setback Monday with closes near lows and losses close to 1%. It's been a while since geopolitical concerns unnerved the market, but Russia's military presence in Ukraine continued to take center stage. The Dow Jones...
Anika Therapeutics (ANIK) Showing Signs Of A Dead Cat Bounce Today
at The Street - Mon Mar 03, 8:55AM CST
Trade-Ideas LLC identified Anika Therapeutics (ANIK) as a "dead cat bounce" (down big yesterday but up big today) candidate
Anika Therapeutics, Inc Surges On Approval, but Is It Overpriced Now?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 8:30AM CST
Anika jumped by a third following the FDA's approval of Monovisc, its single injection treatment for osteoarthritis knee pain. The approval concludes a three year process that began when the FDA voted against approving the therapy in...
This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 2:15PM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
FDA Approval and a Generic-Drug Maker Arms Race Propel Winners
David Williamson, The Motley Fool - Motley Fool - Thu Feb 27, 8:39PM CST
Anika Therapeutics is the big winner in biotech this week, with shares having increased by a third of their value after receiving FDA approval for Monovisc, an osteoarthritis treatment injected directly into the knee. Johnson & Johnson will...
Norcraft Companies Schedules Earnings Release and Conference Call for Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Feb 27, 6:01AM CST
Norcraft Companies, Inc. ("we," the "Company" or "Norcraft") (NYSE:NCFT), a leading manufacturer of kitchen and bathroom cabinetry in the United States and Canada, announced today that the Company will release its fourth quarter and full year 2013 financial results before the market opens on Tuesday, March 25, 2014. A conference call will be held that same day at 10:00 a.m. Eastern time to review fourth quarter and full year 2013 results, discuss recent events and conduct a question-and-answer period.
Chesapeake Energy Falls after Missing Estimates; Anika Therapeutics Gets FDA Approval for Monovisc
ACCESSWIRE - Thu Feb 27, 12:16AM CST
Chesapeake Energy Corporation (NYSE: CHK) - For an in-depth report on Chesapeake Energy Corporation follow: www.BullTrends.com/stockquote/CHK
Anika rises on drug approval
at Investor's Business Daily - Wed Feb 26, 5:42PM CST
The biotech's shares leapt 33.2% to 45.90 a day after it won FDA approval for its arthritis treatment. After the close Tue., Anika Therapeutics (ANIK) said the FDA had approved Monovisc for osteoarthritis of the knee. DePuy Synthes Mitek Sports...
Nasdaq stocks posting largest volume increases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SmarTrend Watching for Potential Pullback in Shares of Anika Therapeutics After 33.16% Gain
Comtex SmarTrend(R) - Wed Feb 26, 4:20PM CST
Anika Therapeutics (NASDAQ:ANIK) traded in a range yesterday that spanned from a low of $43.50 to a high of $52.49. Yesterday, the shares gained 33.2%, which took the trading range above the 3-day high of $35.53 on volume of 6.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Anika Therapeutics, Amyris, and ExamWorks Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 4:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The recipe for market weakness remains the same yet again --...
Stocks Close With Modest Gains, But Homebuilders Surge
at Investor's Business Daily - Wed Feb 26, 3:22PM CST
Major averages managed small gains Wednesday, recovering a bit after getting spooked by comments from Boston Fed President Eric Rosengren. He cited significant job market slack in a speech to the Boston Economic Club. The Dow Jones industrial average...
Anika Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Wed Feb 26, 3:05PM CST
--EPS Increases 42% to $0.44 in Quarter and 70% to $1.39 for Year